Abbott Laboratories Announces Third-Quarter 2025 Results and Reaffirms Guidance

Details

Adjusted diluted EPS was $1.30, up from $1.21 in the prior year. The company reaffirmed its full-year 2025 organic sales growth guidance and narrowed its adjusted diluted EPS guidance range to $5.12 to $5.18. Medical Devices and Established Pharmaceuticals segments showed strong growth, while Diagnostics sales declined due to reduced COVID-19 testing-related sales. Abbott also declared a quarterly dividend of $0.59 per share, payable on November 17, 2025.

Items reported

About Abbott Laboratories

Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.